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Sir,
Hall and Schwarz1 recently proposed in this Journal a scheme for
naming antibiotic resistance genes. Although there may be
advantages to their approach in some cases, we think it is unwork-
able with respect to b-lactamase nomenclature where single
mutations impact enzyme function.2
The argument advanced is that a new allele number should
be assigned when the amino acid sequence differs by ≥2%
from a known sequence. As a result, genes differing by ,2%
will receive the same designation. In the case of b-lactamases,
this approach does not reﬂect our understanding of how these
enzymes have behaved. b-Lactamases have been distinguished
by a single amino acid change since TEM-2 was differentiated
from TEM-1 by isoelectric focusing in 1976.3 More importantly,
single amino acid changes within a b-lactamase family canmark-
edly affect the substrate spectrum or response to b-lactamase
inhibitors. A single substitution changes the penicillinase SHV-1
to the extended-spectrum cephalosporinase SHV-24 and a single
amino acid differentiates inhibitor-resistant SHV-49 from SHV-1.5
Indeed, most of the.220 numbered blaTEM alleles or.190 blaSHV
alleles in a b-lactamase database6 encode enzymes differing
from each other by,2%and so by the Hall and Schwarz1 proposal
would be given the same allele number.
The ﬁrst TEM b-lactamase differing from TEM-1 by ≥2% is
TEM-162 with seven amino acid changes and so by the new
proposal TEM-162 would become TEM-2, while the preceding
160 TEM varieties would need to be distinguished as TEM-1 sub-
types by such inelegant nomenclature as TEM-1-1 to TEM-1-160.
Furthermore, the effect of a few mutations on the resistance
phenotype is not limited tob-lactamases. Only twomutations sep-
arate an acetyltransferase active only on aminoglycosides from
one that also confers quinolone resistance bymodifying ciproﬂoxa-
cin and norﬂoxacin.7 Consequently, we believe that a single amino
acid difference sufﬁces to deﬁne a new resistance allele.
We also take issue with assigning allele numbers only to resist-
ance genes that have been mobilized and not to chromosomally
determined or intrinsic genes. A plasmid location is not always
easy to prove and a chromosomal gene may be just as signiﬁcant
as a mobilized one in determining a clinically important resistance
phenotype. For example, SHV b-lactamase is commonly encoded
on the chromosome of Klebsiella pneumoniae,8 but can also be
plasmid-borne. In both locations, particular blaSHV alleles can pro-
vide a range of resistance phenotypes from resistance to penicillins
only, to activity against oxyimino-b-lactams, to carbapenemase
activity.9,10Distinct resistance alleles should not be denied an allele
designation due to their genetic location.
Lastly, we share the concern thatmuch of the variation uncov-
ered by today’s facile sequencing technology will have uncertain
functional consequences. We urge that allele distinctions be
based on protein and not nucleotide sequence variation where
synonymous codons could create trivial differences.We anticipate
that as WGS becomes the method of choice for pathogen out-
break surveillance, delivering high-resolution understanding of
genomic relationships at low cost, resistance phenotypes will
be increasingly predicted from sequence data. Already, this ap-
proach is being used as a surveillance and even diagnostic
tool.11 Improving predictive methods will require a nomenclature
that provides amino acid-level resolution and that also is robust to
bioinformatics manipulation (e.g. lacks italic and other non-ASCII
characters).
Accordingly, we agree that:
(1) A resistance gene should be shown to encode a product that
decreases antibiotic susceptibility.
(2) To establish uniqueness, the nucleotide sequence must be
determined in full, including a signal sequence if present
(the promoter sequence is not taken into account).
(3) The gene should have been isolated from a natural source and
not generated in the laboratoryas bymutationor recombination.
And add:
(4) A single amino acid difference in the protein product is sufﬁ-
cient to deﬁne a new numbered allele, independent of
whether the responsible gene has a plasmid or chromosomal
location and independent of any documented change in
phenotype.
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(5) These rules do not preclude subgroups within an existing
category such as the currently heterogeneous OXA group of
b-lactamases with.400 members having a variety of resist-
ance phenotypes and species of origin, which are currently
being considered as a basis of subgrouping.
NOTE: The National Center for Biotechnology Information (NCBI)
has taken over the b-lactamase allele assignment from the Lahey
Clinic site and bases its curation efforts and allele assignments
for b-lactamases on these principles so as to encourage phenotypic
characterization (NCBI b-lactamase submissions: http://www.
ncbi.nlm.nih.gov/projects/pathogens/submit_beta_lactamase/).
For other resistance gene classes, NCBI encourages the resist-
ance community to reach a consensus on nomenclature by build-
ing on the principles outlined in this communication. In particular,
we agree that some gene families, such as tetracycline and
macrolide resistance genes, where cut-offs are presently .80%
identity, should be subjected to debate with the possibility of
some genes being renamed.
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